Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts.
HIPEC
adenocarcinoma
colorectal neoplasms
cytoreductive surgery
mucinous carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
30
07
2022
revised:
15
08
2022
accepted:
16
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Mucinous adenocarcinoma is a frequent subtype in colorectal cancer (CRC). A higher initial T-stage, poorer differentiation, worse response to anti-tumor therapies, and shorter survival are characteristic of mucinous CRC. Moreover, the therapeutic benefit of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in mucinous CRC has not been significantly investigated. A retrospective analysis of 218 CRC patients with synchronous or metachronous peritoneal metastases was conducted. 129 and 89 patients had synchronous and metachronous metastases, and 36 (27.8%) and 22 (24.8%) of these were mucinous CRC, respectively. Mucinous CRC was more frequent in the proximal colon, with a higher T-stage and N-stage and with an average peritoneal carcinomatosis index that was 2 values higher. Disease-specific survival was significantly worse in the synchronous mucinous group (median survival: 22.4 months vs. 36.3 months, In the case of synchronous peritoneal metastases originating from mucinous CRC, the positive effect of CRS+HIPEC cannot be verified, and the added value of this highly invasive treatment is therefore somewhat questioned. However, CRS + HIPEC is recommended for metachronous metastases, since no difference between the two CRC-subtypes could be verified.
Sections du résumé
BACKGROUND
BACKGROUND
Mucinous adenocarcinoma is a frequent subtype in colorectal cancer (CRC). A higher initial T-stage, poorer differentiation, worse response to anti-tumor therapies, and shorter survival are characteristic of mucinous CRC. Moreover, the therapeutic benefit of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in mucinous CRC has not been significantly investigated.
METHODS
METHODS
A retrospective analysis of 218 CRC patients with synchronous or metachronous peritoneal metastases was conducted.
RESULTS
RESULTS
129 and 89 patients had synchronous and metachronous metastases, and 36 (27.8%) and 22 (24.8%) of these were mucinous CRC, respectively. Mucinous CRC was more frequent in the proximal colon, with a higher T-stage and N-stage and with an average peritoneal carcinomatosis index that was 2 values higher. Disease-specific survival was significantly worse in the synchronous mucinous group (median survival: 22.4 months vs. 36.3 months,
CONCLUSIONS
CONCLUSIONS
In the case of synchronous peritoneal metastases originating from mucinous CRC, the positive effect of CRS+HIPEC cannot be verified, and the added value of this highly invasive treatment is therefore somewhat questioned. However, CRS + HIPEC is recommended for metachronous metastases, since no difference between the two CRC-subtypes could be verified.
Identifiants
pubmed: 36010972
pii: cancers14163978
doi: 10.3390/cancers14163978
pmc: PMC9406628
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Coloproctol. 2021 Dec;37(6):425-433
pubmed: 34961304
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Mol Cancer. 2017 Feb 2;16(1):33
pubmed: 28153010
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99
pubmed: 15000151
Eur J Cancer. 2016 Jan;53:155-62
pubmed: 26751236
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Clin Invest. 1991 Mar;87(3):1037-45
pubmed: 1999484
Dis Colon Rectum. 2010 Jun;53(6):936-43
pubmed: 20485009
Lancet Oncol. 2021 Feb;22(2):256-266
pubmed: 33476595
Int J Hyperthermia. 2018;35(1):298-304
pubmed: 30130987
Clin Cancer Res. 2013 Jan 15;19(2):462-8
pubmed: 23169436
Ann Surg Oncol. 2004 May;11(5):518-21
pubmed: 15123461
J Surg Oncol. 2001 Aug;77(4):282-3
pubmed: 11473380
Ann Surg Oncol. 2014 Sep;21(9):2963-70
pubmed: 24728741
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
J Clin Oncol. 2004 Aug 15;22(16):3284-92
pubmed: 15310771
Ann Surg Oncol. 2008 May;15(5):1429-39
pubmed: 18301950
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Surg Oncol. 2015 Feb;111(2):237-42
pubmed: 25195780
J Surg Oncol. 2000 Oct;75(2):103-7
pubmed: 11064389
BJS Open. 2019 Jun 27;3(5):585-594
pubmed: 31592510
Cancer Metastasis Rev. 2019 Jun;38(1-2):237-257
pubmed: 30680581
Br J Surg. 2019 May;106(6):682-691
pubmed: 30945755
Ann Surg. 2016 Jun;263(6):1102-11
pubmed: 26756756
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
J Natl Cancer Inst. 2021 Aug 2;113(8):1027-1035
pubmed: 33484560
BMC Cancer. 2019 Apr 25;19(1):390
pubmed: 31023318
Br J Cancer. 2016 Aug 9;115(4):490-6
pubmed: 27404452
Cancer Discov. 2015 Jan;5(1):16-8
pubmed: 25583798
Ann Surg. 2013 Jun;257(6):1065-71
pubmed: 23299520
J Surg Oncol. 2019 Dec;120(7):1190-1200
pubmed: 31536150
Ann Surg Oncol. 2022 May 5;:
pubmed: 35513588
Int J Mol Sci. 2018 Aug 30;19(9):
pubmed: 30200215
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Int J Oncol. 2009 Apr;34(4):1109-15
pubmed: 19287969
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Front Med (Lausanne). 2020 Jun 05;7:205
pubmed: 32582726
Cancer Commun (Lond). 2019 Mar 29;39(1):13
pubmed: 30922401
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
Eur J Surg Oncol. 2018 Feb;44(2):220-227
pubmed: 29258720
Pharmacogenomics J. 2020 Jun;20(3):524-532
pubmed: 31819162
World J Surg Oncol. 2012 Jun 15;10:109
pubmed: 22703761
Chin Med J (Engl). 2009 Jul 5;122(13):1486-91
pubmed: 19719934
Eur J Surg Oncol. 2022 Jun 23;:
pubmed: 35768312
Dis Colon Rectum. 2004 Jan;47(1):78-85
pubmed: 14719155
World J Gastrointest Surg. 2021 Dec 27;13(12):1567-1583
pubmed: 35070064